Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. A user asks about alfatradiol's availability, public perception, and usage in Germany.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The user is excited about an upcoming update for GT20029, expected in March. They express frustration with the negativity on Reddit.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

Pyluritamide and RU58841 are compared for effectiveness in addition to dutasteride for hair loss treatment. Reddit users report great results with RU58841, but data suggests pyluritamide may have better affinity.

A user shared their 7-month progress on hair regrowth using a regimen of dutasteride, minoxidil, stemoxydine, microneedling, and keto shampoo. They noted significant improvement, particularly in vellus hair growth, and discussed the potential addition of RU58841, though they experienced side effects with it previously.

RU58841 is discussed as a treatment that stops scalp itching when used with finasteride or dutasteride. The user is considering trying RU58841 due to persistent itching despite using the "big 3" treatments.

The post is about Bryan Johnson's hair loss regimen, which includes dutasteride mesotherapy, minoxidil, microneedling, and red laser therapy. The conversation includes discussions about the effectiveness of topical dutasteride and speculation about whether Bryan Johnson has had a hair transplant.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The conversation is about hair loss treatments, specifically discussing RU58841, with concerns about its safety and lack of research. Alternatives like finasteride, dutasteride, and minoxidil are mentioned, with some users sharing personal experiences and side effects.

The conversation is about personal experiences with Anagenic Pyrilutamid for hair loss and what carriers people use with it. No specific treatments or outcomes are mentioned.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

The user has been taking dutasteride for 9 months and is satisfied with the hair growth results. They had a hair transplant and don't want to share hairline progress.

The user experienced hair loss and itching after stopping RU58841 and resumed it to stop these symptoms. They also use Dutasteride and question which treatment is effective.

An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.

Dutasteride, taken every other day with vitamin and mineral supplements, successfully increased crown hair density without side effects after seven months. The user plans to leave the subreddit after achieving desired hair regrowth.

The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.

RU58841 powder storage, with differing opinions on whether to store it in the freezer or at room temperature. One user prefers the freezer, while a company suggests room temperature.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The user shared their hair loss treatment progress using oral and topical dutasteride, topical minoxidil, microneedling, and keto shampoo. They plan to possibly add LLLT, PRP with exosomes, and other treatments in the future.